| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | Director
2 companies
Deborah Birx is Chief Executive Officer at ARMP and has filed Form 4s across 2 companies. Deborah Birx's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.8M at current prices.
The biggest single holding is INVA (~$1.2M) as Director.
Deborah Birx has 13 Form 4 filings on record from March 2021 to July 2026, across 2 companies: Chief Executive Officer at Armata Pharmaceuticals (ARMP), 2023–2026; Director at Innoviva (INVA), 2021–2023.
The 18 reported transactions were 7 option or other derivative awards, 6 stock awards and 5 tax withholdings.
There are no priced open-market purchases or sales on record, so none of these filings shows a decision to buy or sell shares in the market.
No transactions found
Try adjusting your filters or search criteria